Regencor Inc. a US-based life sciences company, announced on Wednesday that it has added Philip Janiak, PhD and Ken Mahaffey, MD to its Scientific Advisory Board.

Dr Mahaffey serves as a professor of cardiovascular medicine at the Stanford University School of Medicine. His main area of research is the design and implementation of multicentre clinical trials, concentrating on analyses of important clinical cardiac outcome measures utilising large patient databases. He has headed or served on the Executive Committees for many cardiovascular outcome trials, more than 125 Clinical Endpoint Committees, and multiple Data Safety Monitoring Boards. Dr Mahaffey has also served with the FDA and is a consultant for the Endocrinologic and Metabolic Drugs Advisory Committee.

Dr Janiak started his career at Servier and was the head of Cardiovascular Research at Sanofi. He has extensive experience in the management of international R&D groups and in heading multiple research collaborations with biopharmaceutical companies such as MyoKardia, and academic institutions such as IMI. Currently, Dr Janiak is the CEO of Corteria Pharmaceuticals.